Benoit D Roussel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7456471/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Thrombolysis by PLAT/tPA increases serum free IGF1 leading to a decrease of deleterious autophagy following brain ischemia. Autophagy, 2022, 18, 1297-1317.	9.1	14

 $_{2}$ Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq0 0 0 rgBT /Overlock 10 Jf 50 702 Td (edition $_{1,430}^{2}$

3	Two-Chains Tissue Plasminogen Activator Unifies Met and NMDA Receptor Signalling to Control Neuronal Survival. International Journal of Molecular Sciences, 2021, 22, 13483.	4.1	8
4	Proteostasis During Cerebral Ischemia. Frontiers in Neuroscience, 2019, 13, 637.	2.8	30
5	The role of plasminogen activators in stroke treatment: fibrinolysis and beyond. Lancet Neurology, The, 2018, 17, 1121-1132.	10.2	93
6	Activation of cell surface GRP78 decreases endoplasmic reticulum stress and neuronal death. Cell Death and Differentiation, 2017, 24, 1518-1529.	11.2	56
7	Distant Space Processing is Controlled by tPA-dependent NMDA Receptor Signaling in the Entorhinal Cortex. Cerebral Cortex, 2016, 27, 4783-4796.	2.9	12
8	Progressive myoclonus epilepsy associated with neuroserpin inclusion bodies (neuroserpinosis). Epileptic Disorders, 2016, 18, 103-110.	1.3	22
9	Normalization of Reverse Transcription Quantitative PCR Data During Ageing in Distinct Cerebral Structures. Molecular Neurobiology, 2016, 53, 1540-1550.	4.0	24
10	Adaptive preconditioning in neurological diseases – therapeutic insights from proteostatic perturbations. Brain Research, 2016, 1648, 603-616.	2.2	41
11	The Dual Role of Serpins and Tissue-Type Plasminogen Activator During Stroke. , 2015, , 269-292.		0
12	Molecular pathogenesis of alpha-1-antitrypsin deficiency. Revue Des Maladies Respiratoires, 2014, 31, 992-1002.	1.7	21
13	Endoplasmic reticulum dysfunction in neurological disease. Lancet Neurology, The, 2013, 12, 105-118.	10.2	396
14	Sterol metabolism regulates neuroserpin polymer degradation in the absence of the unfolded protein response in the dementia FENIB. Human Molecular Genetics, 2013, 22, 4616-4626.	2.9	21
15	Structural Dynamics Associated with Intermediate Formation in an Archetypal Conformational Disease. Structure, 2012, 20, 504-512.	3.3	33
16	Characterisation of serpin polymers in vitro and in vivo. Methods, 2011, 53, 255-266.	3.8	31
17	Pituitary adenylate cyclaseâ€activating polypeptide (PACAP) stimulates the expression and the release of tissue plasminogen activator (tPA) in neuronal cells: involvement of tPA in the neuroprotective effect of PACAP. Journal of Neurochemistry, 2011, 119, 920-931.	3.9	18
18	Unravelling the twists and turns of the serpinopathies. FEBS Journal, 2011, 278, 3859-3867.	4.7	42

BENOIT D ROUSSEL

#	ARTICLE	IF	CITATIONS
19	Antibodies Preventing the Interaction of Tissue-Type Plasminogen Activator With N-Methyl- <scp>d</scp> -Aspartate Receptors Reduce Stroke Damages and Extend the Therapeutic Window of Thrombolysis. Stroke, 2011, 42, 2315-2322.	2.0	63
20	The Serpinopathies. Methods in Enzymology, 2011, 501, 421-466.	1.0	35
21	HMGB-1 promotes fibrinolysis and reduces neurotoxicity mediated by tissue plasminogen activator. Journal of Cell Science, 2011, 124, 2070-2076.	2.0	24
22	Pharmacological Activation/Inhibition of the Cannabinoid System Affects Alcohol Withdrawal-Induced Neuronal Hypersensitivity to Excitotoxic Insults. PLoS ONE, 2011, 6, e23690.	2.5	23
23	PPACK-Desmodus rotundus salivary plasminogen activator (cDSPAα1) prevents the passage of tissuetype plasminogen activator (rt-PA) across the blood-brain barrier and neurotoxicity. Thrombosis and Haemostasis, 2009, 102, 606-608.	3.4	3
24	Age and albumin D site-binding protein control tissue plasminogen activator levels: neurotoxic impact. Brain, 2009, 132, 2219-2230.	7.6	36
25	Neuroserpin Polymers Activate NF-κB by a Calcium Signaling Pathway That Is Independent of the Unfolded Protein Response. Journal of Biological Chemistry, 2009, 284, 18202-18209.	3.4	68
26	Cerebrovascular protection as a possible mechanism for the protective effects of NXY-059 in preclinical models: An in vitro study. Brain Research, 2009, 1294, 144-152.	2.2	25
27	Newborn- and Adult-Derived Brain Microvascular Endothelial Cells Show Age-Related Differences in Phenotype and Glutamate-Evoked Protease Release. Journal of Cerebral Blood Flow and Metabolism, 2009, 29, 1146-1158.	4.3	26
28	Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic. Trends in Neurosciences, 2009, 32, 48-55.	8.6	256
29	Toward Safer Thrombolytic Agents in Stroke: Molecular Requirements for NMDA Receptor-Mediated Neurotoxicity. Journal of Cerebral Blood Flow and Metabolism, 2008, 28, 1212-1221.	4.3	74
30	Anti-NR1 N-terminal-domain vaccination unmasks the crucial action of tPA on NMDA-receptor-mediated toxicity and spatial memory. Journal of Cell Science, 2007, 120, 578-585.	2.0	66
31	RecombinantDesmodus rotundusSalivary Plasminogen Activator Crosses the Blood–Brain Barrier Through a Low-Density Lipoprotein Receptor-Related Protein-Dependent Mechanism Without Exerting Neurotoxic Effects. Stroke, 2007, 38, 1036-1043.	2.0	55
32	Tissue-type plasminogen activator rescues neurones from serum deprivation-induced apoptosis through a mechanism independent of its proteolytic activity. Journal of Neurochemistry, 2006, 98, 1458-1464.	3.9	66